TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05434390

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Estoy PrEParado/ I am PrEPared intervention
Description: Participants will receive an Information, Motivation, and Behavioral skills model PrEP intervention tailored for mixed immigrant status Latino men who have sex with men

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Participants will be offered PrEP navigation services as part of usual care at the study site.
Study: NCT04841616

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic Ultrasound -Guided Fine Needle Biopsy
Description: Patients will undergo EUS FNB with the 22-gauge FNB needle (Acquire®, Boston Scientific Natick, MA). After each pass, the needle is removed and the stylet will be introduced into the needle to extrude any aspirated material on a glass slide for inspection of the presence of a macroscopic visible core (MVC). The total length of the MVC will be measured before placement into a formalin bottle. EUS-FNB is completed if the obtained MVC is longer than 4mm and deemed adequate by endoscopist. If the obtained MVC is \< 4mm, the procedure is repeated until a MVC of ≥ 4mm is obtained and deemed adequate by endoscopist. A maximum of 7 passes is allowed.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Contrast-Enhanced Harmonic Endoscopic Ultrasound
Description: After initial evaluation, 2.5ml of second-generation contrast media, SonoVueTM (Bracco, Ceriano Laghetto, Italy), will be injected. After infusion, the point of puncture will be determined when the parenchyma of the pancreas was enhanced. The contrast-enhanced area was identified and then the biopsy was directed toward that area, while avoiding unenhanced (i.e. necrotic) areas and not changing the target lesion. Rest of the procedure is identical with that in conventional EUS arm.
Study: NCT05648292

Intervention type: BEHAVIORAL
Intervention: Neuropsychological tests and psychological questionnaires
Description: * The clinical group will complete:~  * the BCcogSEP: a comprehensive neuropsychological examination~ * the IAM and I WILL BE tasks; experimental neuropsychological tasks to assess autobiographical memory, future thinking and personal identity~ * A series of questionnaires including the BRIEF COPE, the Connor Davidson Resilience Scale, the Satisfaction with Life Scale and the Hospital Anxiety and Depression Scale, which respectively assess coping strategies, resilience, life satisfaction and anxiety/depression~* The control group will complete:~  * the IAM and I WILL BE tasks; experimental neuropsychological tasks to assess autobiographical memory, future thinking and personal identity~ * A series of questionnaires including the BRIEF COPE, the Connor Davidson Resilience Scale, the Satisfaction with Life Scale and the Hospital Anxiety and Depression Scale, which respectively assess coping strategies, resilience, life satisfaction and anxiety/depression

Intervention type: BEHAVIORAL
Intervention: Neuropsychological tests and psychological questionnaires
Description: * The clinical group will complete:~  * the BCcogSEP: a comprehensive neuropsychological examination~ * the IAM and I WILL BE tasks; experimental neuropsychological tasks to assess autobiographical memory, future thinking and personal identity~ * A series of questionnaires including the BRIEF COPE, the Connor Davidson Resilience Scale, the Satisfaction with Life Scale and the Hospital Anxiety and Depression Scale, which respectively assess coping strategies, resilience, life satisfaction and anxiety/depression~* The control group will complete:~  * the IAM and I WILL BE tasks; experimental neuropsychological tasks to assess autobiographical memory, future thinking and personal identity~ * A series of questionnaires including the BRIEF COPE, the Connor Davidson Resilience Scale, the Satisfaction with Life Scale and the Hospital Anxiety and Depression Scale, which respectively assess coping strategies, resilience, life satisfaction and anxiety/depression
Study: NCT05755139

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IPL with smart diagnostic handpiece
Description: treatment with IPL following diagnostic with SMART system
Study: NCT06104904

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: MAPP
Description: Behavioral intervention based on exposure therapy strategies.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MAPP
Description: Behavioral intervention based on exposure therapy strategies.
Study: NCT05620888

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Walk behavior change: Tailored messages (TM)
Description: Every afternoon at the same time, the mobile application sends a message to the participants of the TM arm. The message is tailored based on the answers provided to the pre-intervention questionnaire. An example message is: you think you are not able to walk regularly when your morale is low: do not give up because physical activity is also good for the mood! The intervention is provided for 30 days.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Walk behavior change: Non tailored messages (NTM)
Description: Every afternoon at the same time, the mobile application sends a message to the participants of the NTM arm. The message concerns the emotional well-being resulting from the performance of the physical activity and is not tailored. An example message is: walking regularly in the fresh air improves your mood. The intervention is provided for 30 days.
Study: NCT05428631

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implantation of the CARDIOMEMS™ HF device
Description: The initial routine workup includes a nephrological evaluation: mGFR with Iohexol before fitting the CARDIOMEMS™ HF device, renal echo-Doppler, urinary sedimentation, etiological assessment of severe Chronic Kidney Disease, NT-ProBNP, impedancemetry, urinary ionogram, weight, anemia assessment, and correction of possible iron and/or vitamin deficiency and a cardiology evaluation: blood pressure, heart rate, clinical data, biology (Complete Blood Count, iono, urea, creatinine, total bilirubin, ferritin, CST), echocardiography (Left Ventricle Ejection Fraction, E/A, E/e', indexed volume of the left atrium, Tricuspid Annular Plane Systolic Excursion, Tissue Doppler S-wave, surface area of the right atrium, Systolic Pulmonary Artery Pressure, Right Atrial Pressure). The device will be implanted in the selected patients by Pr François Roubille at Montpellier University Hospital within 1 month of the pre-inclusion visit. It will monitor their pulmonary artery pressure.
Study: NCT05314998

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: 85 mg/m2 D1 over 2 hours every; 14 days, 12 cycles, 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 85 mg/m2 D1 over 2 hours every; 14 days, 12 cycles, 24 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan
Description: 150 mg/m2 D1 over 90 minutes to begin 30 min after the Folinic acid infusion is started; every 14 days, 12 cycles, 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: 150 mg/m2 D1 over 90 minutes to begin 30 min after the Folinic acid infusion is started; every 14 days, 12 cycles, 24 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Folinic acid
Description: 400 mg/m2 (racemic mixture) (or 200 mg/m2 if L-folinic acid is used), IV infusion over 2 hours; every 14 days, 12 cycles, 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folinic acid
Description: 400 mg/m2 (racemic mixture) (or 200 mg/m2 if L-folinic acid is used), IV infusion over 2 hours; every 14 days, 12 cycles, 24 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-fluorouracil
Description: 2.4 g/m2 IV continuous infusion over 46 hours (1200 mg/m2/ day); every 14 days, 12 cycles, 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil
Description: 2.4 g/m2 IV continuous infusion over 46 hours (1200 mg/m2/ day); every 14 days, 12 cycles, 24 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: 1000mg/m2 is given as an IV infusion over 30 minutes; on day 1, 8 and 15 out of 28 days (= 1 cycle); Repeated 6 times (i.e., 6 cycles) for 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1000mg/m2 is given as an IV infusion over 30 minutes; on day 1, 8 and 15 out of 28 days (= 1 cycle); Repeated 6 times (i.e., 6 cycles) for 24 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: 1660mg/m2/day in two divided doses administered orally for 21 days followed by 7 days' rest (one cycle) for six cycles i.e. 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 1660mg/m2/day in two divided doses administered orally for 21 days followed by 7 days' rest (one cycle) for six cycles i.e. 24 weeks
Study: NCT04639024

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADCT-301
Description: Patients will receive ADCT-301 37.5 ug/kg infused day 1,8, and 15 of a q3week cycle. Patients will have up to 2 cycles to assess response and safety to therapy and if they are not progressing may continue for up to 6 cycles.
Study: NCT05396911

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: UP2UTobacco
Description: The universal prevention program was designed as a group intervention to include components of effective tobacco control programs for youth and young adults. The intervention lasts approximately 45 minutes and is delivered in a classroom setting, utilizing a Socratic teaching style and evoking participation using the principles of motivational interviewing. UP2UTobacco targets all tobacco products with the goals to enhance motivation for youth to quit tobacco or remain tobacco-free, reduce intentions to use tobacco, promote peer discussions around the impact of using tobacco, and correct cognitive misperceptions around tobacco use.
Study: NCT04713163

Intervention type: DRUG
Intervention: covid19 vaccine
Description: Vaccine

Intervention type: DRUG
Intervention: covid19 vaccine
Description: Vaccine
Study: NCT05783336

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stepping Stones and Creating Futures Plus (SSCF+)
Description: Group-based intervention delivered to small friendship networks, by a facilitator.
Study: NCT04703426

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sargramostim (GM-CSF)
Description: Drug that binds to the protein PD-1 to help immune cells kill cancer cells better, it is given as an intravenous injection through a vein.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab (anti-PD-1)
Description: Drug that stimulates blood cells that may help support the immune system during cancer treatment, given as intravenous infusion
Study: NCT05024734

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin
Description: In PDOs from patients that show highest response to Epirubicin, this drug will be instilled intravesically once weekly for 6 times.~Epirubicin is also the default drug, in case of failure of drug prediction in the in-vitro drug screen in PDO.~Epirubicin will be used as a concentrate for injection/instillation 2 mg/ml in total 50mg per vial. Prior to use, the concentrate for injection is diluted with 25ml of 0.9% saline solution to obtain the final Solution with 1mg/ml of Epirubicin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitomycin
Description: In PDOs from patients that show highest response to Mitomycin, this drug will be instilled intravesically once weekly for 6 times.~Mitomycin C will be used as 20mg dry powder. Prior to use, the powder will be dissolved in 50ml of 0.9% saline solution according to the manufacturer instructions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: In PDOs from patients that show highest response to Gemcitabine, this drug will be instilled intravesically once weekly for 6 times.~Gemcitabine will be used as 2000 mg/50ml. For intravesical application, 1000mg of gemcitabine (corresponding to 25ml) will be diluted in 25ml 0.9% saline solution, to obtain the gemcitabine concentration of 1000mg/50ml used for instillation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: In PDOs from patients that show highest response to Docetaxel, this drug will be instilled intravesically once weekly for 6 times.~Docetaxel will be used as 140mg/7ml solution. For intravesical application, 48.825ml of saline will be added to 1.875ml Docetaxel solution (according 37.5mg of Docetaxel). The concentration of this solution is 0.74mg/ml by a total volume of the instillation solution of 50,7.
Study: NCT05972005

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The Intervention (Stronger at Home Intervention)
Description: The home-based intervention includes 8 visits by a PT and/or PTA. The PT conducts 3 visits for initial assessment, program design, coaching, and discharge assessments. The program targets personal goals and provides pain self-management support. The second PT visit at 6 weeks allows for reassessment and adjustments. The intervention ensures adherence through multiple sessions, tailored exercises, barrier-solving support, and motivational strategies. The PTA conducts solo visits every other week, assisting with exercises and education under PT supervision. This inclusion reduces wait times and improves efficiency. The clinical team consists of at least 2 PTs and 2 PTAs trained for 3 days. The exercise program adheres to evidence-based principles, involving a 30-minute session with warm-up, exercise, and cool-down. Participants are encouraged to exercise 5 times a week, focusing on strengthening, balance, and functionality. Feasible compliance rates were observed in the pilot study.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care (Control)
Description: The control group will receive usual home care provided by the healthcare system, which could vary between cases. We'll document their received care during follow-ups as it is inconsistent and poorly recorded. Regular check-in calls by the study coordinator will remind them of assessments, reducing attrition.
Study: NCT05984680

Intervention type: OTHER
Group type: OTHER
Intervention: Surveys and Interviews - Arm A
Description: For Arm A, this outpatient study will administer surveys, interviews, concept mapping exercises, guided tours of oncology clinics, design team workshops, and phone calls for follow-up questions
Study: NCT06059508

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-5495 for injection
Description: SHR-5495 for injection
Study: NCT05984680

Intervention type: OTHER
Group type: OTHER
Intervention: COPD Care Pathway
Description: The COPD care pathway will consist of an initial assessment followed by monthly follow-up assessments, which occur during regularly scheduled immunotherapy infusions. At each of these three visits, the study team will administer symptom measures, counsel participants on the management of COPD, and give algorithm-generated general recommendations to the patient and provider regarding possible options for COPD-directed care.
Study: NCT05865522

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Trapezius Massage
Description: The patients in Trapezius Massage Group will be given classical massage to the trapezius muscle for 6 weeks, 2 sessions per week (12 sessions in total) by the researcher in the physical therapy unit.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Foot Massage
Description: The patients in Foot Massage Group will be given foot massage for 6 weeks, 2 sessions per week (12 sessions in total) by the researcher in the physical therapy unit.
Study: NCT05233592

Intervention type: DEVICE
Intervention: CGM
Description: Patients wear a CGM to measure the effects of the COVID-19 booster vaccine on blood sugar levels.
Study: NCT06579963

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cool roof
Description: Cool roofs are a sunlight reflecting roof coating that can reduce indoor temperature. Cool roofs have high solar reflectance (reflecting the ultraviolet and visible wavelengths of sunlight, reducing heat transfer to the surface of a roof) and high thermal emittance (radiating absorbed solar energy).
Study: NCT05038865

Intervention type: OTHER
Intervention: Malocclusion and Orthodontic Treatment
Description: Group 1 is exposed to malocclusion and orthodontic treatment. However, the inclusion in the study does not affect the treatment since it is an observational study.~The exposure of group 2 is no malocclusion, no orthodontic treatment.
Study: NCT06108154

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational breastfeeding traning session
Description: Educational breastfeeding training session base on dialogical, visual attractive and training session on Proper LATCH techniques and breastfeeding positions to prevent from nipplesoreness.
Study: NCT05754359

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: I'm an Active Hero (IAAH) Intervention Program
Description: The I'm an Active Hero (IAAH) programme is a 10-week intervention aimed at increasing physical activity and decreasing sedentary behaviour in preschool-aged (aged 3-5 years) children. It is anticipated to begin in February 2023 to May 2023. Assessments will be conducted at baseline and immediately following the intervention. The IAAH-intervention will be implemented by the preschool teachers, who will have two teacher training sessions with the main researcher (myself). The IAAH-intervention involves environmental modifications (a classroom) to create areas with sufficient space for active play; classroom sessions these will be implemented for 10 weeks (a minimum of one hour per week); and parent involvement, such as the provision of parental-child interaction homework activities and written information (tip cards, posters, and newsletters). for parents on how to encourage their children to be active.
Study: NCT04999111

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad26.COV2.S
Description: Participants will receive IM injection of Ad26.COV2.S.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad26.COV2.S
Description: Participants will receive IM injection of Ad26.COV2.S.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad26.COV2.S
Description: Participants will receive IM injection of Ad26.COV2.S.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad26.COV2.S
Description: Participants will receive IM injection of Ad26.COV2.S.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad26.COV2.S
Description: Participants will receive IM injection of Ad26.COV2.S.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad26.COV2.S
Description: Participants will receive IM injection of Ad26.COV2.S.
Study: NCT05516576

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: endomina®
Description: Endoscopic gastroplasty
Study: NCT05845788

Intervention type: PROCEDURE
Intervention: Peripheral nerve block
Description: Ultrasound guided peripheral nerve block

Intervention type: PROCEDURE
Intervention: Peripheral nerve block
Description: Ultrasound guided peripheral nerve block
Study: NCT06650436

Intervention type: DIAGNOSTIC_TEST
Intervention: EEG
Description: The phase lag index will be used to assess functional connectivity between time series based on the consistency with which one signal is leading or lagging with respect to another signal.The PLI characterizes the asymmetry in the distribution of instantaneous phase differences between signals. If such an asymmetry is present, a phase coupling is assumed between signals, reflecting synchronized activity. Importantly, zero-phase coupling is discarded in the PLI as this may represent activity from common sources picked up at different electrodes. Based on the MST, network measures can be calculated. It is a measure of network efficiency. Leaf fraction quantifies the fraction of nodes in the whole network that have only one connecting edge, which is a measure of network integration.

Intervention type: DIAGNOSTIC_TEST
Intervention: EEG
Description: The phase lag index will be used to assess functional connectivity between time series based on the consistency with which one signal is leading or lagging with respect to another signal.The PLI characterizes the asymmetry in the distribution of instantaneous phase differences between signals. If such an asymmetry is present, a phase coupling is assumed between signals, reflecting synchronized activity. Importantly, zero-phase coupling is discarded in the PLI as this may represent activity from common sources picked up at different electrodes. Based on the MST, network measures can be calculated. It is a measure of network efficiency. Leaf fraction quantifies the fraction of nodes in the whole network that have only one connecting edge, which is a measure of network integration.
Study: NCT05654168

Intervention type: DIAGNOSTIC_TEST
Intervention: Imaging
Description: The thickness of the musculature to be studied will be measured with ultrasonography
Study: NCT06650436

Intervention type: DIAGNOSTIC_TEST
Intervention: MRI
Description: Manual segmentation of the acute ischemic lesion will be performed on MRI of the brain. Support vector regression-based lesion symptom mapping (SVR-LSM) will be performed to determine the association between AIL location and PSD. We will also perform an assumption-free region of interest (ROI)-based analysis by using support vector regression. The ROIs will be determined by the AAL atlas and ICBM-DTI-81 white matter tract atlas in MNI-152 space.~The MRI's will be performed within 72 hours of the stroke onset with a follow-up of 12 months.

Intervention type: DIAGNOSTIC_TEST
Intervention: MRI
Description: Manual segmentation of the acute ischemic lesion will be performed on MRI of the brain. Support vector regression-based lesion symptom mapping (SVR-LSM) will be performed to determine the association between AIL location and PSD. We will also perform an assumption-free region of interest (ROI)-based analysis by using support vector regression. The ROIs will be determined by the AAL atlas and ICBM-DTI-81 white matter tract atlas in MNI-152 space.~The MRI's will be performed within 72 hours of the stroke onset with a follow-up of 12 months.

Intervention type: DIAGNOSTIC_TEST
Intervention: Depression screening and neuropsychological tests
Description: Screening post-stroke delirium (during first 72hours after stroke symptom onset):~4AT test score: 0-12 (\>/= 4: diagnosis of (post-stroke) delirium) RASS score: from -5 until +4 Screening post-stroke cognitive impairment (3months, 12 months): MOCA score: 0-30~Screening post-stroke depression:~Patient Health Questionnaire-2: score 0-6 Hospital Anxiety and Depression Scale: score 0-21Anxiety and 0-21Depression

Intervention type: DIAGNOSTIC_TEST
Intervention: Depression screening and neuropsychological tests
Description: Screening post-stroke delirium (during first 72hours after stroke symptom onset):~4AT test score: 0-12 (\>/= 4: diagnosis of (post-stroke) delirium) RASS score: from -5 until +4 Screening post-stroke cognitive impairment (3months, 12 months): MOCA score: 0-30~Screening post-stroke depression:~Patient Health Questionnaire-2: score 0-6 Hospital Anxiety and Depression Scale: score 0-21Anxiety and 0-21Depression